2025-520978-18-00Not yet recruitingPhase 1
A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease
Source: EU CTIS (euclinicaltrials.eu) · Last updated 20 Jul 2026
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 14 Oct 2025
- Start date
- 5 Feb 2026
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Chronic kidney disease
- EU CT number
- 2025-520978-18-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 44
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy volunteers and for people with chronic kidney disease to test the safety and effects of a study drug called OJR520.
- Age
- 18 years or older
- Sex
- All sexes can join.
Read by machine on 9 Nov 2026.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Research Organisation GmbH | Berlin | Germany | Not yet recruiting |
| Arensia Clinics S.R.L. | Bucharest | Romania | Not yet recruiting |
| Spitalul Clinic Judetean De Urgenta Cluj | Cluj-Napoca | Romania | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.